Kaneka Corp. v. Xiamen Kingdomway Group Co.

790 F.3d 1298, 115 U.S.P.Q. 2d (BNA) 1001, 2015 U.S. App. LEXIS 9634, 2015 WL 3613644
CourtCourt of Appeals for the Federal Circuit
DecidedJune 10, 2015
Docket2014-1373, 2014-1399
StatusPublished
Cited by44 cases

This text of 790 F.3d 1298 (Kaneka Corp. v. Xiamen Kingdomway Group Co.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Kaneka Corp. v. Xiamen Kingdomway Group Co., 790 F.3d 1298, 115 U.S.P.Q. 2d (BNA) 1001, 2015 U.S. App. LEXIS 9634, 2015 WL 3613644 (Fed. Cir. 2015).

Opinion

Kaneka Corporation sued Defendants Xiamen Kingdomway Group Company, Pacific Rainbow International Inc., and Shen-zhou Biology and Technology Co., Ltd., in the Central District of California, alleging infringement of U.S. Patent No. 7,910,340 (the '340 Patent). The district court granted summary judgment of nonin-fringement based on the district court’s claim construction. Kaneka appealed. For the reasons that follow, we affirm-in-part, vacate-in-part, and remand.

BACKGROUND

Coenzyme Q10 exists in animal cells. Cells use coenzyme Q10 to produce adeno-sine triphosphate, which aids cellular respiration. Coenzyme Q10 assists adenosine triphosphate production through redox reactions, in which the coenzyme gives up and gains electrons. Both oxidized and reduced coenzyme Q10 are sold as dietary supplements. „

Kaneka owns the '340 Patent, which describes processes for producing oxidized and reduced coenzyme Q10. The claims at issue in this appeal describe processes for producing oxidized coenzyme Q10. Independent claim 1 recites:

1. A process for producing on an industrial scale the oxidized coenzyme Q10 represented by the following formula:
[[Image here]]
which comprises culturing reduced coen-zyme Q10 producing microorganisms in a culture medium containing a carbon source, a nitrogen source, a phosphorus source and a micronutrient to obtain microbial cells containing reduced coen-zyme Q10 at a ratio of not less than 70 mole % among the entire coenzymes Q10, disrupting the microbial cells to obtain reduced coenzyme Q10; and
oxidizing ‘ thus-obtained reduced coen-zyme Q10 to oxidized coenzyme Q10 and then extracting the oxidized coenzyme Q10 by an organic solvent under an inert gas atmosphere.

*1302 '340 Patent col. 23 1. 56-col. 24 1. 25; J.A. 80 (certificate of correction) (emphasis added to disputed language).

Claim 11 is identical to claim 1 except the extraction step is recited before the oxidation step. '340 Patent col. 24 1. 50-col. 25 1. 6 (“extracting the reduced coen-zyme Q10 by an organic solvent under an inert gas atmosphere, and oxidizing the extracted reduced coenzyme Q10 to oxidized coenzyme Q10”).

Independent claims 22 and 33 are identical to claims 1 and 11, respectively, except that the extraction step recited in claims 22 and 33 is carried out in a “sealed tank.” Claim 22, like claim 1, recites the oxidation step before the extraction step. Id. col. 25 11. 32-54 (“oxidizing thus-obtained reduced coenzyme Q10 to oxidized coenzyme Q10 and then extracting the oxidized coenzyme Q10 by an organic solvent in a sealed tank”) (emphasis added to disputed language). Claim 33 is identical to claim 22 except the extraction step is recited before the oxidation step. Id. col. 26 11. 13-36 (“extracting the reduced coenzyme Q10 by an organic solvent in a sealed tank, and oxidizing the extracted reduced coenzyme Q10 to oxidized coenzyme Q10”) (emphasis added to disputed language).

On March 22, 2011, Kaneka filed suit in the Central District of California, asserting independent claims 1, 11, 22, and 33, along with respective dependent claims. In June, Kaneka filed a Section 337 Petition in the U.S. International Trade Commission (“Commission”) involving the same claims. The district court stayed the lawsuit pending resolution of the Commission proceeding. The Commission issued a decision finding no infringement by any' of the respondents.

Following the conclusion of the Commission proceeding, the district court lifted the stay and construed the asserted claims. The court construed the term “inert gas atmosphere” to mean “a gas atmosphere that is free or substantially free of oxygen and reactive gases.” J.A. 3578. The “culturing” step was construed such that the mole ratio of reduced coenzyme Q10 relative to all the coenzyme Q10 in the process would be measured at a certain point in the process according to a particular assay described in the '340 Patent. J.A. 14051. The court construed the term “sealed tank” to mean “a tank that is closed to prevent the entry or exit of materials.” J.A. 3579. The “oxidizing” step of claims 1 and 22 was construed to mean “actively converting all or substantially all of the reduced coenzyme Q10 obtained from the disruption step to oxidized coenzyme Q10 in a step before beginning the extraction step,” while the “oxidizing” step of claims 11 and 33 was construed to mean “actively converting all or substantially all of the extracted reduced coenzyme Q10 obtained from the disruption step to oxidized coen-zyme Q10 in a separate step after the extraction step has been performed.” J.A. 3585-86.

Based on the district court’s claim construction, Defendants moved for summary judgment of noninfringement with respect to claims 1, 11, 22, 33, and associated dependent claims. The district court found an absence of a genuine issue of material fact that Defendants’ accused process does not infringe on the basis of the court’s construction of three claim terms: “inert gas atmosphere,” “sealed .tank,” and the “oxidizing” step. Kaneka appealed from the district court’s summary judgment, challenging the district court’s claim construction. We have jurisdiction under 28 U.S.C. § 1295(a)(1).

Disoussion

We first address whether Kaneka waived the right to challenge certain argu *1303 ments regarding the district court’s grant of summary judgment. Shenzhou contends that although Kaneka argued claim construction in its opening brief, Kaneka failed to identify a genuine issue of material fact as to whether Appellees would infringe the asserted claims under Kaneka’s proposed construction.

We disagree. For the reasons that follow, the district court’s grant of summary judgment of noninfringement rests on an erroneous claim construction. Hence, a genuine issue of material fact concerning infringement may exist under the proper construction. See Wilson Sporting Goods Co. v. Hillerich & Bradsby Co., 442 F.3d 1322, 1326 (Fed.Cir.2006) (“[T]he legal function of giving meaning to claim terms always takes place in the context of a specific accused infringing device or process.”). Summary judgment should ordinarily be vacated or reversed if the district court bases summary judgment on an erroneous claim construction. Innovad Inc. v. Microsoft Corp., 260 F.3d 1326, 1335 (Fed.Cir.2001).

We review a district court’s grant of summary judgment according to the law of the regional circuit, here the Ninth Circuit, where summary judgment is reviewed de novo. Halo Elecs., Inc. v. Pulse Elecs., Inc., 769 F.3d 1371, 1377 (Fed.Cir.2014) (citing Humane Soc’y of U.S. v. Locke,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
790 F.3d 1298, 115 U.S.P.Q. 2d (BNA) 1001, 2015 U.S. App. LEXIS 9634, 2015 WL 3613644, Counsel Stack Legal Research, https://law.counselstack.com/opinion/kaneka-corp-v-xiamen-kingdomway-group-co-cafc-2015.